Paratek Pharmaceuticals, Inc.
Simbolis: PRTK
NASDAQ
2.23
USDRinkos kaina šiandien
-3.0521
P/E santykis
0.1791
PEG koeficientas
127.83M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Paratek Pharmaceuticals, Inc. (PRTK) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 178.97 | 34.2 | 95.5 | 125.2 | |||||||||||||||||||||
balance-sheet.row.short-term-investments | 29.92 | 0 | 15.1 | 20 | |||||||||||||||||||||
balance-sheet.row.net-receivables | 190.45 | 78 | 33.1 | 15.7 | |||||||||||||||||||||
balance-sheet.row.inventory | 62.72 | 16.6 | 11 | 14.6 | |||||||||||||||||||||
balance-sheet.row.other-current-assets | 41.91 | 7.9 | 12.4 | 7.8 | |||||||||||||||||||||
balance-sheet.row.total-current-assets | 474.42 | 136.8 | 152.1 | 164.1 | |||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 8.63 | 2.4 | 2.6 | 3 | |||||||||||||||||||||
balance-sheet.row.goodwill | 3.32 | 0.8 | 0.8 | 0.8 | |||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 3.32 | 0.8 | 0.8 | 0.8 | |||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 140.11 | 32.5 | 28.4 | 8.9 | |||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 152.06 | 35.7 | 31.8 | 12.7 | |||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-assets | 626.48 | 172.5 | 183.9 | 176.9 | |||||||||||||||||||||
balance-sheet.row.account-payables | 21.68 | 5.3 | 5.4 | 1.8 | |||||||||||||||||||||
balance-sheet.row.short-term-debt | 164.04 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 872.3 | 258.4 | 255.7 | 252 | |||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||||||
balance-sheet.row.other-current-liab | 91.2 | 32.1 | 25.9 | 22.1 | |||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1042.35 | 306.2 | 280.4 | 255.2 | |||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.89 | 1.5 | 1.3 | 1.5 | |||||||||||||||||||||
balance-sheet.row.total-liab | 1354.08 | 343.6 | 311.7 | 279.1 | |||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.common-stock | 0.23 | 0.1 | 0.1 | 705.5 | |||||||||||||||||||||
balance-sheet.row.retained-earnings | -3769.48 | -930.4 | -866.9 | -807.8 | |||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.12 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3041.77 | 759.4 | 739.1 | 0 | |||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | -727.6 | -171 | -127.8 | -102.3 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 626.48 | 172.5 | 183.9 | 176.8 | |||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-equity | -727.6 | -171 | -127.8 | -102.3 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 626.48 | - | - | - | |||||||||||||||||||||
Total Investments | 29.92 | 0 | 15.1 | 20 | |||||||||||||||||||||
balance-sheet.row.total-debt | 1036.34 | 258.4 | 255.7 | 252 | |||||||||||||||||||||
balance-sheet.row.net-debt | 887.3 | 224.2 | 175.4 | 146.9 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -62.73 | -63.6 | -59.1 | -96.5 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.31 | 0.5 | 0.4 | 0.6 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 1.1 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 10.34 | 12.3 | 14.3 | 10.2 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 23.96 | -20.8 | -8.2 | -20.3 | |||||||||||||||||||
cash-flows.row.account-receivables | -5.71 | -40.4 | -21.8 | -7.5 | |||||||||||||||||||
cash-flows.row.inventory | -2.05 | -9.1 | -15.5 | -11.8 | |||||||||||||||||||
cash-flows.row.account-payables | 8.96 | 7.7 | 6.8 | 1.6 | |||||||||||||||||||
cash-flows.row.other-working-capital | 22.76 | 21 | 22.3 | -2.6 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 4.91 | 5.4 | 4.3 | 1.5 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -23.22 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.07 | 0 | -0.4 | -0.4 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -15.16 | -15.2 | -15.1 | -29.6 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 30 | 30 | 20 | 122.5 | |||||||||||||||||||
cash-flows.row.other-investing-activites | 15.2 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 29.97 | 14.8 | 4.5 | 92.5 | |||||||||||||||||||
cash-flows.row.debt-repayment | -3.73 | -2.9 | -0.3 | -70 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 7.3 | 18.4 | 21.9 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.other-financing-activites | -0.12 | 0.7 | 0.3 | 59.4 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -3.57 | 5.1 | 18.3 | 11.3 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 3.18 | -46.2 | -25.4 | 0.4 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 149.55 | 34.4 | 80.6 | 106 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 146.37 | 80.6 | 106 | 105.6 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | -23.22 | -66.1 | -48.3 | -103.4 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -0.07 | 0 | -0.4 | -0.4 | |||||||||||||||||||
cash-flows.row.free-cash-flow | -23.29 | -66.2 | -48.6 | -103.8 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 167.74 | 150.8 | 121 | 43.5 | ||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 25.3 | 23.1 | 21.5 | 8.7 | ||||||||||||||||||||||
income-statement-row.row.gross-profit | 142.45 | 127.7 | 99.4 | 34.9 | ||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
income-statement-row.row.research-development | 38.83 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.other-expenses | -7.38 | -9.5 | -9.2 | -3.4 | ||||||||||||||||||||||
income-statement-row.row.operating-expenses | 186.99 | 173.9 | 140.5 | 110.4 | ||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 212.29 | 197 | 162.1 | 119 | ||||||||||||||||||||||
income-statement-row.row.interest-income | 0.99 | 0.8 | 0.1 | 1.5 | ||||||||||||||||||||||
income-statement-row.row.interest-expense | 18.86 | 18.1 | 17.4 | 20.2 | ||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -12.98 | -17.3 | -17.4 | -21 | ||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -7.38 | -9.5 | -9.2 | -3.4 | ||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -12.98 | -17.3 | -17.4 | -21 | ||||||||||||||||||||||
income-statement-row.row.interest-expense | 18.86 | 18.1 | 17.4 | 20.2 | ||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.95 | 1.3 | 0.4 | 1.6 | ||||||||||||||||||||||
income-statement-row.row.ebitda-caps | -43.4 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.operating-income | -44.54 | -46.2 | -41.1 | -75.5 | ||||||||||||||||||||||
income-statement-row.row.income-before-tax | -62.56 | -63.5 | -58.5 | -96.5 | ||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 4.56 | 0.1 | 0.6 | 19.7 | ||||||||||||||||||||||
income-statement-row.row.net-income | -67.12 | -63.6 | -59.1 | -116.3 |
Dažnai užduodami klausimai
Kas yra Paratek Pharmaceuticals, Inc. (PRTK) bendras turtas?
Paratek Pharmaceuticals, Inc. (PRTK) bendras turtas yra 172538000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 67270000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.850.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.190.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.299.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.201.
Kas yra Paratek Pharmaceuticals, Inc. (PRTK) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -63566000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 258414000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 173941000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 42685000.000.